Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies

被引：4
作者：
Sureda, Anna [1 ]
Dreger, Peter [2 ,3 ]
Bishop, Michael R. [4 ]
Kroger, Nicolaus [5 ]
Porter, David L. [6 ,7 ]
机构：
[1] Hosp Barcelona, Inst Catala Oncol, Hematol Dept, Barcelona, Spain
[2] Heidelberg Univ, Dept Med 5, Heidelberg, Germany
[3] European Soc Blood & Marrow Transplantat EBMT, Leiden, Netherlands
[4] Univ Chicago, Hematopoiet Cellular Therapy Program, Sect Hematol Oncol, Chicago, IL 60637 USA
[5] Univ Med Ctr, Dept Stem Cell Transplantat, Hamburg, Germany
[6] Univ Penn, Div Hematol Oncol, Blood & Marrow Transplant Program, Philadelphia, PA 19104 USA
[7] Perelman Sch Med, Philadelphia, PA 19104 USA
来源：
BONE MARROW TRANSPLANTATION | 2019年 / 54卷 / 01期
关键词：
CHRONIC LYMPHOCYTIC-LEUKEMIA; DIAGNOSED MULTIPLE-MYELOMA; PROGRAMMED DEATH-1 BLOCKADE; 2ND INTERNATIONAL WORKSHOP; HIGH-DOSE CHEMOTHERAPY; BRENTUXIMAB VEDOTIN; CONSOLIDATION THERAPY; ALLOGENEIC TRANSPLANTATION; CONDITIONING REGIMENS; HODGKINS LYMPHOMA;
D O I：
10.1038/s41409-018-0214-5
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
Relapse is now the major cause of treatment failure after allogeneic HSCT (alloHSCT). Many novel strategies to address this critical issue are now being developed and tested. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg, Germany in November 2016, international experts presented and discussed recent developments in the field. Some approaches may be applicable to a wide range of patients after transplant, whereas some may be very disease-specific. We present a report from the session dedicated to issues related to prevention and treatment of relapse of lymphoid malignancies after alloHSCT. This session included detailed reviews as well as forward-looking commentaries that focused on Hodgkin lymphoma, chronic lymphocytic leukemia and mantle cell lymphoma, diffuse large cell and follicular lymphoma, and multiple myeloma.
引用
收藏
页码：17 / 25
页数：9
相关论文
共 83 条
  • [1] Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway
    Abu-Eid, Rasha
    Samara, Raed N.
    Ozbun, Laurent
    Abdalla, Maher Y.
    Berzofsky, Jay A.
    Friedman, Kevin M.
    Mkrtichyan, Mikayel
    Khleif, Samir N.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2014, 2 (11) : 1080 - 1089
  • [2] NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies
    Alyea, Edwin P.
    DeAngelo, Daniel J.
    Moldrem, Jeffrey
    Pagel, John M.
    Przepiorka, Donna
    Sadelin, Michel
    Young, James W.
    Giralt, Sergio
    Bishop, Michael
    Riddell, Stan
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (08) : 1037 - 1069
  • [3] Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
    Armand, Philippe
    Shipp, Margaret A.
    Ribrag, Vincent
    Michot, Jean-Marie
    Zinzani, Pier Luigi
    Kuruvilla, John
    Snyder, Ellen S.
    Ricart, Alejandro D.
    Balakumaran, Arun
    Rose, Shelonitda
    Moskowitz, Craig H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3733 - +
  • [4] Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
    Armand, Philippe
    Nagler, Arnon
    Weller, Edie A.
    Devine, Steven M.
    Avigan, David E.
    Chen, Yi-Bin
    Kaminski, Mark S.
    Holland, H. Kent
    Winter, Jane N.
    Mason, James R.
    Fay, Joseph W.
    Rizzieri, David A.
    Hosing, Chitra M.
    Ball, Edward D.
    Uberti, Joseph P.
    Lazarus, Hillard M.
    Mapara, Markus Y.
    Gregory, Stephanie A.
    Timmerman, John M.
    Andorsky, David
    Or, Reuven
    Waller, Edmund K.
    Rotem-Yehudar, Rinat
    Gordon, Leo I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (33) : 4199 - 4206
  • [5] Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
    Attal, Michel
    Lauwers-Cances, Valerie
    Marit, Gerald
    Caillot, Denis
    Moreau, Philippe
    Facon, Thierry
    Stoppa, Anne Marie
    Hulin, Cyrille
    Benboubker, Lofti
    Garderet, Laurent
    Decaux, Olivier
    Leyvraz, Serge
    Vekemans, Marie-Christiane
    Voillat, Laurent
    Michallet, Mauricette
    Pegourie, Brigitte
    Dumontet, Charles
    Roussel, Murielle
    Leleu, Xavier
    Mathiot, Claire
    Payen, Catherine
    Avet-Loiseau, Herve
    Harousseau, Jean-Luc
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (19) : 1782 - 1791
  • [6] Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
    Barlogie, Bart
    Pineda-Roman, Mauricio
    Van Rhee, Frits
    Haessler, Jeff
    Anaissie, Elias
    Hollmig, Klaus
    Alsayed, Yazan
    Waheed, Sarah
    Petty, Nathan
    Epstein, Joshua
    Shaughnessy, John D., Jr.
    Tricot, Guido
    Zangari, Maurizio
    Zeldis, Jerome
    Barer, Sol
    Crowley, John
    [J]. BLOOD, 2008, 112 (08) : 3115 - 3121
  • [7] Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party
    Bazarbachi, Ali
    Boumendil, Ariane
    Finel, Herve
    Mohty, Mohamad
    Castagna, Luca
    Peggs, Karl S.
    Blaise, Didier
    Afanasyev, Boris
    Diez-Martin, Jose L.
    Sierra, Jorge
    Bloor, Adrian
    Martinez, Carmen
    Robinson, Stephen
    Malladi, Ram
    El-Cheikh, Jean
    Corradini, Paolo
    Montoto, Silvia
    Dreger, Peter
    Sureda, Anna
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (01) : 86 - 96
  • [8] Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome
    Brown, J. R.
    Kim, H. T.
    Armand, P.
    Cutler, C.
    Fisher, D. C.
    Ho, V.
    Koreth, J.
    Ritz, J.
    Wu, C.
    Antin, J. H.
    Soiffer, R. J.
    Gribben, J. G.
    Alyea, E. P.
    [J]. LEUKEMIA, 2013, 27 (02) : 362 - 369
  • [9] Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
    Brudno, Jennifer N.
    Somerville, Robert P. T.
    Shi, Victoria
    Rose, Jeremy J.
    Halverson, David C.
    Fowler, Daniel H.
    Gea-Banacloche, Juan C.
    Pavletic, Steven Z.
    Hickstein, Dennis D.
    Lu, Tangying L.
    Feldman, Steven A.
    Iwamoto, Alexander T.
    Kurlander, Roger
    Maric, Irina
    Goy, Andre
    Hansen, Brenna G.
    Wilder, Jennifer S.
    Blacklock-Schuver, Bazetta
    Hakim, Frances T.
    Rosenberg, Steven A.
    Gress, Ronald E.
    Kochenderfer, James N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) : 1112 - +
  • [10] Castagna L, 2017, BONE MARROW TRANSPL, V52, P797, DOI 10.1038/bmt.2017.26
123456789